These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34865343)

  • 1. [Optimal timing of antiviral therapy for chronic HBV-infected patients with normal ALT].
    Gui HL; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2020 Dec; 28(12):988-991. PubMed ID: 34865343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant histological changes and satisfying antiviral efficacy in chronic hepatitis B virus infection patients with normal alanine aminotransferase. Antiviral therapy decision in chronic HBV patients with normal ALT.
    Wu Z; Ma AL; Xie Q; Zhang XQ; Cheng J; Zhang DZ; Wang GQ; Zhao H
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101463. PubMed ID: 32571749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
    Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
    Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.
    Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH
    J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of individuals with chronic hepatitis B virus infection and persistent normal or mildly elevated aminotransferase levels.
    Yan JY; Li ZQ; Yu ZJ; Kan QC
    J Cell Biochem; 2019 Apr; 120(4):6632-6641. PubMed ID: 30368885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection.
    Chang X; Wang J; Chen Y; Long Q; Song L; Li Q; Liu H; Shang Q; Yu Z; Jiang L; Xiao G; Li L; Chen L; Wang X; Li Z; Chen D; Dong Z; An L; Tan L; Chen Y; Yang Y
    EBioMedicine; 2021 May; 67():103389. PubMed ID: 34004423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
    Papatheodoridis GV; Manesis EK; Manolakopoulos S; Elefsiniotis IS; Goulis J; Giannousis J; Bilalis A; Kafiri G; Tzourmakliotis D; Archimandritis AJ
    Hepatology; 2008 Nov; 48(5):1451-9. PubMed ID: 18924246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A retrospective study on the liver pathological characteristics and the effect of antiviral treatment for 1 to 7 years old children with heptitis B e antigen negative chronic hepatitis B].
    Zhu SS; Dong Y; Wang LM; Xu ZQ; Chen DW; Gan Y; Wang FC; Yan JG; Cao LL; Wang P; Zhang M; Zhang HF
    Zhonghua Er Ke Za Zhi; 2016 Aug; 54(8):587-91. PubMed ID: 27510870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.
    Wu IC; Lai CL; Han SH; Han KH; Gordon SC; Chao YC; Tan CK; Sievert W; Tanwandee T; Xu D; Neo BL; Chang TT
    Hepatology; 2010 Apr; 51(4):1185-9. PubMed ID: 20044806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of liver histological changes and a sustained virological response to peginterferon among chronic hepatitis B e antigen-positive patients with normal or minimally elevated alanine aminotransferase levels.
    Chen J; Xu CR; Xi M; Hu WW; Tang ZH; Zang GQ
    J Viral Hepat; 2017 Jul; 24(7):573-579. PubMed ID: 28107601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NIH consensus development statement on management of hepatitis B.
    Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
    NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognosis and management of inactive HBV carriers.
    Invernizzi F; Viganò M; Grossi G; Lampertico P
    Liver Int; 2016 Jan; 36 Suppl 1():100-4. PubMed ID: 26725905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HBV: Do I treat my immunotolerant patients?
    Vlachogiannakos J; Papatheodoridis GV
    Liver Int; 2016 Jan; 36 Suppl 1():93-9. PubMed ID: 26725904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A model to predict antiviral treatment in HBeAg negative chronic hepatitis B with alanine aminotransferase≤2 upper limit of normal.
    Gao S; Fan YC; Zhao J; Sun FK; Han J; Zhao ZH; Wang K
    Liver Int; 2014 Aug; 34(7):e229-37. PubMed ID: 24112455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical characteristics of hepatic flare and efficacy of antiviral therapy in pregnant women with chronic hepatitis B virus infection].
    Ding Y; Sheng QJ; Zhang C; Wu YY; Yuan SY; Xia TT; An ZY; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Feb; 27(2):106-111. PubMed ID: 30818914
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa.
    Shimakawa Y; Njie R; Ndow G; Vray M; Mbaye PS; Bonnard P; Sombié R; Nana J; Leroy V; Bottero J; Ingiliz P; Post G; Sanneh B; Baldeh I; Suso P; Ceesay A; Jeng A; Njai HF; Nayagam S; D'Alessandro U; Chemin I; Mendy M; Thursz M; Lemoine M
    J Hepatol; 2018 Oct; 69(4):776-784. PubMed ID: 30104154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early antiviral treatment response in HBeAg-positive chronic HBV infected-patients with high viral load and normal ALT].
    Huang Y; Du BY; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2023 Mar; 31(3):233-237. PubMed ID: 37137846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
    Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
    Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of HBV DNA levels, HBV mutations and biochemical parameters during antiviral therapy in a patient with HBeAg-negative chronic hepatitis B.
    Sa-nguanmoo P; Tangkijvanich P; Payungporn S; Chieochansin T; Thawornsuk N; Chongsrisawat V; Poovorawan Y
    Asian Pac J Allergy Immunol; 2007; 25(2-3):183-8. PubMed ID: 18035807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.